ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Historical Holders from Q3 2020 to Q3 2025

Symbol
ALXO on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
53.1M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
27.8M
Holdings value
$51.3M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
60
Number of buys
16
Number of sells
-38
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Redmile Group, LLC 8.5% $2.04M 4.64M Redmile Group, LLC 30 Jun 2025
HBM Healthcare Investments (Cayman) Ltd. 8.4% +27.1% $2.3M $547K 4.5M +31.3% HBM Healthcare Investments (Cayman) Ltd. 31 Mar 2025
TANG CAPITAL PARTNERS LP 6.3% $1.68M 3.3M TANG CAPITAL MANAGEMENT, LLC 31 Dec 2024
MILLENNIUM MANAGEMENT LLC 6% +18% $5.71M $861K 3.19M +17.8% Millennium Management LLC 17 Oct 2025
FMR LLC 3.4% $917K 1.8M FMR LLC 29 Nov 2024

Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 27.8M $51.3M +$2.4M $1.83 60
2025 Q2 29M $12.1M -$2.78M $0.42 58
2025 Q1 34.8M $21.7M -$4.3M $0.62 83
2024 Q4 41M $68.5M -$8.51M $1.67 85
2024 Q3 45.5M $83.1M -$40.2M $1.82 90
2024 Q2 48.5M $292M -$2.83M $6.03 107
2024 Q1 45.8M $510M -$5.82M $11.15 105
2023 Q4 45.8M $681M +$185M $14.89 93
2023 Q3 33.3M $160M -$6.35M $4.80 75
2023 Q2 34.3M $257M -$6.38M $7.51 74
2023 Q1 35.7M $161M -$6M $4.52 85
2022 Q4 36.4M $411M -$2.05M $11.27 85
2022 Q3 36.4M $349M +$5.42M $9.57 96
2022 Q2 35.9M $291M -$16.6M $8.09 92
2022 Q1 36.8M $622M +$2.85M $16.90 94
2021 Q4 36.3M $780M -$55.9M $21.49 103
2021 Q3 34.5M $2.55B +$110M $73.86 113
2021 Q2 33.3M $1.82B -$28.5M $54.68 102
2021 Q1 33.5M $2.47B +$80.5M $73.74 90
2020 Q4 32.3M $2.78B +$439M $86.20 89
2020 Q3 27.3M $1.03B +$1.03B $37.74 56